Lee Kevin C, Eisig Sidney B, Perrino Michael A
Resident, Division of Oral and Maxillofacial Surgery, NewYork-Presbyterian/Columbia University Medical Center, New York, NY.
Chairman, Division of Oral and Maxillofacial Surgery, NewYork-Presbyterian/Columbia University Medical Center, New York, NY.
J Oral Maxillofac Surg. 2018 Aug;76(8):1719-1724. doi: 10.1016/j.joms.2018.03.002. Epub 2018 Mar 8.
After discectomy, interpositional implants (IPIs) are believed to provide temporomandibular joint stability and protect against degenerative joint space remodeling. Alloplastic IPIs gained popularity in the late 1970s because the practice showed early success without donor site morbidity. Unfortunately, these implants were subject to substantial fragmentation resulting in an exuberant foreign body giant cell response that progressively eroded adjacent structures. Most of these alloplastic implants were removed in the years following their recall by the US Food and Drug Administration in 1991, however some remained in circulation. This report describes a case of a failed Proplast/Teflon IPI 27 years after its placement. This case highlights the considerations for managing a patient with a Proplast/Teflon IPI and serves to remind providers that, although increasingly rare, these implants are still present and subject to delayed failure.
椎间盘切除术后，植入物被认为可提供颞下颌关节稳定性，并防止关节间隙发生退行性重塑。异质植入物在20世纪70年代末开始流行，因为这种做法早期取得了成功，且没有供区并发症。不幸的是，这些植入物会发生大量碎裂，导致过度的异物巨细胞反应，进而逐渐侵蚀相邻结构。1991年美国食品药品监督管理局召回这些植入物后的几年里，大多数异质植入物都被取出，但仍有一些在流通。本报告描述了一例Proplast/Teflon植入物植入27年后失效的病例。该病例强调了处理Proplast/Teflon植入物患者时的注意事项，并提醒医疗人员，尽管这些植入物越来越少见，但仍然存在，且可能出现延迟失效。
